Usan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 50 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.48 M
as on 17-07-2024
- Revenue 65.46%
(FY 2023)
- Profit 249.56%
(FY 2023)
- Ebitda 180.52%
(FY 2023)
- Net Worth 36.31%
(FY 2023)
- Total Assets 72.06%
(FY 2023)
About Usan Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.48 M.
Julie Jaswa and Vimal Jaswa serve as directors at the Company.
- CIN/LLPIN
U24239MH1974PTC017730
- Company No.
017730
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Aug 1974
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Usan Pharmaceuticals Private Limited offer?
Usan Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine.
Who are the key members and board of directors at Usan Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vimal Jaswa  | Managing Director | 26-Apr-2001 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Julie Jaswa | Director | 15-Mar-2019 | Current |
Financial Performance of Usan Pharmaceuticals.
Usan Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 65.46% increase. The company also saw a substantial improvement in profitability, with a 249.56% increase in profit. The company's net worth Soared by an impressive increase of 36.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Usan Pharmaceuticals?
In 2023, Usan Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Andhra Bank Creation Date: 26 Nov 1984 | ₹0.14 M | Open |
Usan Pharmaceuticale Pvt. Creation Date: 17 Apr 1984 | ₹0.32 M | Open |
State Bank Of India Creation Date: 28 Oct 1980 | ₹0.03 M | Open |
How Many Employees Work at Usan Pharmaceuticals?
Unlock and access historical data on people associated with Usan Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Usan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Usan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
